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Abstract
Protein tyrosine kinase 6 (PTK6), also called breast tumor kinase (BRK), is expressed in epithelial cells of various tissues
including the prostate. Previously it was shown that PTK6 is localized to epithelial cell nuclei in normal prostate, but
becomes cytoplasmic in human prostate tumors. PTK6 is also primarily cytoplasmic in the PC3 prostate adenocarcinoma cell
line. Sequencing revealed expression of wild type full-length PTK6 transcripts in addition to an alternative transcript lacking
exon 2 in PC3 cells. The alternative transcript encodes a 134 amino acid protein, referred to here as ALT-PTK6, which shares
the first 77 amino acid residues including the SH3 domain with full length PTK6. RT-PCR was used to show that ALT-PTK6 is
coexpressed with full length PTK6 in established human prostate and colon cell lines, as well as in primary cell lines derived
from human prostate tissue and tumors. Although interaction between full-length PTK6 and ALT-PTK6 was not detected,
ALT-PTK6 associates with the known PTK6 substrates Sam68 and b-catenin in GST pull-down assays. Coexpression of PTK6
and ALT-PTK6 led to suppression of PTK6 activity and reduced association of PTK6 with tyrosine phosphorylated proteins.
While ALT-PTK6 alone did not influence b-catenin/TCF transcriptional activity in a luciferase reporter assay, it enhanced
PTK6-mediated inhibition of b-catenin/TCF transcription by promoting PTK6 nuclear functions. Ectopic expression of ALT-
PTK6 led to reduced expression of the b-catenin/TCF targets Cyclin D1 and c-Myc in PC3 cells. Expression of tetracycline-
inducible ALT-PTK6 blocked the proliferation and colony formation of PC3 cells. Our findings suggest that ALT-PTK6 is able
to negatively regulate growth and modulate PTK6 activity, protein-protein associations and/or subcellular localization. Fully
understanding functions of ALT-PTK6 and its impact on PTK6 signaling will be critical for development of therapeutic
strategies that target PTK6 in cancer.
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Introduction
Protein tyrosine kinase 6 (PTK6), also known as breast tumor
kinase (BRK) in humans and Src-related intestinal kinase (Sik) in
the mouse, is structurally related to Src, but is a member of a
distinct family [1,2]. PTK6 was first discovered in a screen for
tyrosine kinases expressed in human cultured melanocytes [3], and
it was later cloned from human breast cancer cells [4] and the
gastrointestinal tract of the mouse [5]. PTK6 expression has been
detected in differentiated epithelial cells of the gastrointestinal tract
[5,6,7,8,9], oral epithelium [10], prostate [8,11], skin [3,6,12], and
lymphocytes [13]. Studies suggest that PTK6 promotes differen-
tiation in normal epithelia [12,14,15]. In normal intestine, PTK6
also negatively regulates growth [15] and promotes DNA-damage
induced apoptosis [16,17].
Although PTK6 is not expressed in normal mammary gland or
ovarian tissue [7,18], it is expressed in a high percentage of breast
[4,18,19,20] and ovarian cancers that have been examined [21].
Several studies indicate that PTK6 promotes oncogenic signaling
in breast cancer cells (reviewed in [1,22]). While PTK6 is
expressed in normal prostate, the intracellular localization of
PTK6 changes in prostate cancers; it is nuclear in normal prostate
epithelial cells, but relocalizes to the cytoplasm in prostate cancer
[11]. A variety of data now suggest that functions of PTK6 may
depend on its intracellular localization, access to specific substrates
and the tissue in which it is expressed ([23,24,25] and reviewed in
[1]).
The Wnt/b-catenin/TCF signaling pathway plays an important
role in the growth of many different cancers including those of the
prostate (reviewed in [26,27]). We recently demonstrated that b-
catenin is a direct substrate of PTK6, and that PTK6 regulates b-
catenin transcriptional activity in the human SW620 colon cancer
cell line, and in the mouse intestine [23]. The precise functions
that b-catenin signaling plays in prostate cancer are not well
understood, and its complexity is further compounded by crosstalk
of b-catenin with multiple signaling pathways involving factors
such as the androgen receptor [28], IGF-1 (insulin-like growth
factor 1) [29,30], AKT [29,31], osteopontin [32,33], and FoxO
PLoS ONE | www.plosone.org 1 March 2011 | Volume 6 | Issue 3 | e14789(Forkhead box O) [34,35,36]. PTK6 may also be activated by
IGF-1 [37,38] and osteopontin [39]. In addition, PTK6 regulates
AKT [15,17,40,41], FKHR/FoxO1 [15,41] and FoxO3 [42].
There can also be competition between different signaling
pathways for b-catenin interactions, such as FoxO and TCF,
resulting in transactivation of different genes ([43] and reviewed in
[35,44]). Downregulation of Wnt/b-catenin signaling in cancer is
an attractive therapeutic target, and may be achieved by treatment
with various inhibitors (reviewed in [45]).
An alternatively spliced PTK6 transcript that encodes a 15 kDa
protein including the PTK6 SH3 domain and a unique proline-
rich carboxy-terminus was previously detected in the T47D
human breast cancer cell line [46]. Functions of this alternative
PTK6 isoform, originally called lm5 but referred to here as ALT-
PTK6 (alternative PTK6 isoform), have not been explored. We
found that ALT-PTK6 transcripts are present in human prostate
epithelial cell lines derived from normal prostate and prostate
adenocarcinomas, as well as in a variety of human cell lines. We
have examined potential roles of ALT-PTK6 and found that
PTK6 functions, including its ability to regulate b-catenin/TCF
transcription, can be influenced by ALT-PTK6. Knowing the
functions of ALT-PTK6 may be important for devising PTK6
targeted therapies.
Results
Two PTK6 transcripts are expressed in prostate and colon
tumor cell lines
Altered intracellular localization of PTK6 in prostate cancer
cells, including the PC3 cell line [11], raised the possibility that the
PTK6 gene might harbor mutations that contribute to altered
PTK6 localization. We analyzed the sequence of PCR-amplified
reverse-transcribed PTK6 mRNA and compared it to the PTK6
cDNA sequence in the database (accession NM_005975). No
mutations within the PTK6 sequences of PC3 cells were identified,
however the expression of the ALT-PTK6 transcript was confirmed
in PC3 cells (Figure 1). The RNA and protein expression of both
full-length PTK6 and ALT-PTK6 was previously reported in the
T47D human breast cancer cell line [46].
To examine expression of the ALT-PTK6 transcript in a variety
of human cell lines, primers specific to exon 1 (forward) and 3
(reverse) were designed to distinguish the PCR products from full
length PTK6 (407 bp) and ALT-PTK6 (285 bp) transcripts. Both
PTK6 and ALT-PTK6 transcripts were expressed concomitantly in
human prostate (BPH1, DU145, PC3) and colon (HCT116,
LIM1215, SW480) cell lines (Figure 1B). Expression of b-actin
served as a control. Levels of PTK6 transcripts containing exon 2,
which includes the full length PTK6 transcript but not ALT-PTK6,
and exon 8, which would encompass both full-length PTK6 and
ALT-PTK6, were also quantified using real time qRT-PCR and
primers specific to either exon 2 or exon 8 (Figure S1 A). Values
for each cell line were normalized to cyclophilin; to account for
differences in primer efficiencies, transcript levels determined by
primers specific to exons 2 and 8 were normalized to each other
using the pcDNA3-PTK6 expression construct, which contains
both exons 2 and 8 at a 1:1 ratio (Figure S1 B). The ratios of exon
8 to exon 2 were also determined (Figure S1 C). The HepG2 liver
cancer cell line does not express PTK6 and is a negative control.
Expression of PTK6 and ALT-PTK6 was also analyzed in
primary cultures of normal epithelial cells derived from fourteen
prostates (peripheral zone) and epithelial cells from fifteen prostate
adenocarcinomas using PCR (Figure 1D). Both full-length and
ALT-PTK6 transcripts were observed in cell lines derived from
normal prostate and prostate tumors. However, prostate cancer
cells express higher levels of the transcript encoding full length
PTK6 (Figure 1D and E). We have found that the protein encoded
by the full length transcript promotes growth of PC3 cells when it
is localized to the cytoplasm [25]. Unfortunately, neither
commercial antibodies specific for the amino-terminus shared by
PTK6 and ALT-PTK6 that were available at the time of this
study, nor the antibody stocks that originally detected expression
of both proteins [46] (a kind gift from Dr. Mark Crompton)
detected either endogenous protein in our hands. Despite multiple
attempts, we were unsuccessful in raising monoclonal antibodies
against ALT-PTK6.
ALT-PTK6 inhibits phosphorylation of PTK6
Although ALT-PTK6 was first described in 1997 [46], the
potential significance of its expression has not been studied. To
better understand the functions of ALT-PTK6, we generated a
Myc-epitope tagged ALT-PTK6 expression construct. HEK293
cells that do not express endogenous PTK6 were transiently
transfected with a constant amount of constitutively active PTK6
YF and increasing amounts of ALT-PTK6. Immunoblotting
showed decreasing tyrosine phosphorylation of proteins in total
cell lysates with increasing ALT-PTK6 (Figure 2A). Although we
detected some decrease in the levels of ectopic PTK6 YF when
increasing levels of ALT-PTK6 were introduced, greater inhibi-
tion of overall tyrosine phosphorylation was observed. Similar
results were observed following co-transfection of ALT-PTK6 with
PTK6 YF in the PC3 cell line (data not shown). Immunoprecip-
itation of equivalent levels of PTK6 YF revealed that addition of
ALT-PTK6 resulted in decreased association of PTK6 with
tyrosine-phosphorylated proteins (Figure 2B). Even at a PTK6
YF:ALT-PTK6 ratio of 1:1, association of PTK6 with phospho-
tyrosine proteins decreased. Tyrosine phosphorylation of a band
near 50 kDa that corresponds to PTK6 also decreased, and higher
levels of ALT-PTK6 reduced phospho-PTK6 levels even further.
The impact that ALT-PTK6 expression had on protein tyrosine
phosphorylation was quantified in Figure 2C. As is the case with
Src, PTK6 activity is regulated by intramolecular interactions of
the SH2 domain and phosphorylated carboxy-terminal tyrosine,
as well as by SH3 domain binding to the proline rich linker region
between the SH2 and catalytic domains [47,48,49]. However, we
did not detect ALT-PTK6 association with full length PTK6 in co-
immunoprecipitation experiments (Figure 2B).
While the major tyrosine phosphorylated proteins associated
with PTK6 were not identified in Figure 2B, we did detect ALT-
PTK6 association with known PTK6 substrates and interacting
proteins. Total cell lysates prepared from PC3 cells were incubated
with GST or GST-tagged ALT-PTK6 fusion protein and GST
pull down assays were performed. Association of the PTK6
substrates Sam68 [50] and b-catenin [23] with ALT-PTK6 was
readily detected (Figure 2D). These data demonstrate that ALT-
PTK6 participates in protein-protein interactions and may
compete with the full-length protein.
ALT-PTK6 enhances nuclear functions of PTK6
Recently, full length PTK6 was shown to inhibit b-catenin/
TCF transcription [23]. Although transcriptional inhibition of b-
catenin did not require PTK6 kinase activity, we observed direct
interaction between PTK6 and b-catenin [23]. To determine if
ALT-PTK6 can influence b-catenin/TCF mediated transcription
we used the Super 8X TOPFlash (TOPFlash) luciferase reporter
construct [51]. HEK293 cells were co-transfected with TOPFlash,
b-catenin and increasing levels of ALT-PTK6 plasmids. Addition
of ALT-PTK6 did not alter TOPFlash reporter activity
(Figure 3A). As expected, co-transfection of b-catenin and
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Interestingly, when increasing levels of ALT-PTK6 were co-
expressed with TOPFlash, b-catenin, and PTK6 YF, luciferase
reporter activity was further repressed (Figure 3B).
In our previous work, we showed that the subcellular
localization of PTK6 influenced the ability of PTK6 to regulate
b-catenin transcriptional activity [23]. To determine if ectopic
ALT-PTK6 expression had an impact on the intracellular
localization of PTK6 in HEK293 cells, transfected cells were
fractionated and localization of PTK6 and ALT-PTK6 was
examined by immunoblotting. PTK6 YF and ALT-PTK6 were
detected using Myc-epitope specific antibody, and the majority of
both PTK6 isoforms localized to the cytoplasm (Figure 3C).
However, increased expression of ALT-PTK6 resulted in a dose-
dependent decrease of PTK6 YF at the membrane and, more
importantly, an increase in nuclear PTK6 YF (Figure 3C and D).
ALT-PTK6 enhances PTK6-mediated repression of
b-catenin/TCF target genes in prostate tumor cells
Enhanced nuclear localization of PTK6 can contribute to the
repression of b-catenin/TCF targets [23]. Since ALT-PTK6 led to
repression of the b-catenin/TCF luciferase reporter (Figure 3B), we
examined the impact of ALT-PTK6 expression on the growth
promoting targets of b-catenin/TCF. To determine if PTK6 and
ALT-PTK6 can regulate b-catenin/TCF signaling in prostate cancer
cells, PC3 cells were transfected with a constant amount of PTK6 YF
Figure 1. Expression of PTK6 transcripts. A) PTK6 gene structure and its products. The PTK6 gene contains 8 exons. The transcript encoding full
length PTK6 contains all eight exons, but alternative splicing results in exclusion of exon 2 in ALT-PTK6. The PTK6 transcript encodes the full,
catalytically active 451 amino acid protein, while the ALT-PTK6 transcript encodes a protein that shares the first 77 amino acids (including the amino-
terminus and SH3 domain) with full length protein, and also contains a 57 amino acid novel, truncated proline rich carboxyl-terminus due to a frame
shift (striped area). Primers for semi-quantitative PCR that distinguish between full length and ALT-PTK6 are specific to exons 1 and 3 (arrows). B)
Semi-quantitative RT-PCR analysis shows that both PTK6 and ALT-PTK6 (ALT) transcripts are expressed in human prostate and colon cell lines. The
HepG2 liver cancer cell line does not express PTK6 and was used as a negative control. C) Quantification of PTK6 (grey bars) and ALT-PTK6 (white bars)
shown in B normalized to a b-actin loading control shows higher levels of PTK6 expression compared with ALT-PTK6 transcript. D) Both full length and
ALT-PTK6 transcripts are expressed in primary cultures of normal human prostate epithelial cells from the peripheral zone (Normal), as well as in
primary epithelial cultures from prostate adenocarcinomas (Cancer). E) Quantification of PTK6 and ALT-PTK6 transcripts expressed in normal prostate
epithelial cells (black bars) and prostate tumor cells (white bars) shown in D. The ratio of PTK6 over ALT-PTK6 from individual samples was graphed in
order from highest to lowest within cancer and normal sample groups (Top). The cancer and normal sample group mean was calculated with
standard error of mean (SEM) as error bars (bottom). Prostate tumor cells have a higher PTK6 to ALT-PTK6 ratio than normal prostate cells. The asterisk
(*) corresponds to a P-value of ,0.05.
doi:10.1371/journal.pone.0014789.g001
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TCF transcriptional targets Cyclin D1 and c-Myc were observed in
cells transfected with PTK6 YF (Figure 4A, - ALT-PTK6), similar to
what we previously observed in the SW620 colon cancer cell line
[23]. Introduction of ALT-PTK6 resulted in enhanced repression of
the b-catenin target genes compared with PTK6 YF alone. Levels of
b-catenin were not affected. Levels of Cyclin D1, c-Myc and b-
catenin were quantified and normalized to b-actin (Figure 4B).
ALT-PTK6 inhibits proliferation and colony formation of
PC3 prostate tumor cells
Activation of b-catenin/TCF regulated transcription often
contributes to tumor cell growth [52]. To determine if ALT-PTK6
can affect growth, stable PC3 cell lines expressing tetracycline-
inducibleALT-PTK6 were generated.Indirectimmunofluorescence
was performed to examine localization of induced ALT-PTK6
(ALT) and endogenous full length PTK6, and we found that both
proteins are predominantly cytoplasmic (Figure 5A, left panel).
Expression levels and cytoplasmic localization of ALT-PTK6 were
also examined by cell fractionation followed by immunoblotting
(Figure 5A, right panel). Induced expression of ALT-PTK6 did not
have a detectable impact on endogenous PTK6 expression or
intracellular localization in PC3 cells (Figure 5A). However, PC3
cells expressing ALT-PTK6 had reduced proliferation compared
with the uninduced control (Figure 5B). In agreement with the
reduction in cell proliferation data, colony formation of ALT-PTK6
expressing cells was also significantly inhibited compared with
uninduced control cells (Figure 5C). These results suggest that ALT-
PTK6 has a negative effect on growth in prostate cancer cells, which
correlates with its ability to enhance repression of b-catenin/TCF
regulated transcription (Figures 3 and 4).
Discussion
Our work, as well as the work of others, suggests that PTK6
subcellular localization influences its functions [11,23,24,25,53].
PTK6 is localized to the cytoplasm of PC3 cells and this cell line
provides a model for assessing the mechanisms underlying altered
PTK6 intracellular localization in prostate cancer. While a
mutation within the PTK6 gene was not identified, we found that
PC3 cells express both wild type full length PTK6 and alternatively
spliced ALT-PTK6 transcripts. The exclusion of exon 2 results in a
frame shift producing a transcript with an early stop codon, which
encodes a 134 amino acid protein that shares its amino terminus
and SH3 domain with full length PTK6, and contains a novel
proline rich carboxy-terminal sequence (Figure 1A) [46]. Analysis
of PTK6 transcripts expressed in BPH1, DU145 and PC3 prostate
cell lines, and HCT116, LIM1215 and SW480 colon cancer cell
lines showed the presence of full-length and alternatively spliced
transcripts (Figure 1B and Figure S1 B). ALT-PTK6 expression
does not appear to be restricted by cell type, and is expressed in
breast [46], prostate, and colon tumor cell lines (Figure 1B). Both
transcripts were detected in normal prostate cells, as well as
prostate tumor cells, suggesting that ALT-PTK6 is not restricted to
cancer cells (Figure 1C). Prostate tumor cells had a higher PTK6 to
ALT-PTK6 ratio than normal prostate cells. If protein levels are
representative, this suggests an additional mode of aberrant PTK6
function in prostate cancer, along with upregulation and
mislocalization. Interestingly, PTK6 itself could have an impact
on the regulation of alternative splicing, since PTK6 substrates
include a number of RNA binding proteins such as Sam68, SLM1,
and SLM2 [50,53], as well as PSF [54] that regulate splicing
[55,56,57,58].
A variety of proteins contain catalytic domains, which are
essential for specific enzymatic functions. Other regions mediate
binding, allowing proper positioning within the cell or conferring
substrate specificity. The SH2 and SH3 domains mediate protein
interactions and help to regulate enzymatic activity by stabilizing
specific protein conformations. Expression of ALT-PTK6 led to a
reduction of full length PTK6 YF protein tyrosine phosphoryla-
tion, as well as reduced phosphorylation of putative PTK6
substrates (Figure 2B). PTK6 activity is modulated by intramo-
Figure 2. ALT-PTK6 inhibits PTK6 phosphorylation and PTK6 association with other tyrosine-phosphorylated proteins. A) HEK293
cells were co-transfected with constitutively active PTK6 YF and ALT-PTK6. A dose-dependent reduction in tyrosine phosphorylation of proteins was
detected in total cell lysates (TCL). Empty vector was used to keep the total levels of transfected plasmid DNA equal. B) Immunoprecipitation of
comparable levels of PTK6 shows reduced association between PTK6 and tyrosine-phosphorylated proteins (PY), in addition to reduced tyrosine
phosphorylation of PTK6 itself. Arrows correspond to PTK6, and asterisks (*) denote IgG from the immunoprecipitation. Short (SE) and long (LE)
exposures are shown. C) Quantification of tyrosine-phosphorylated PTK6 and several binding partners normalized to total pulled-down PTK6 shows
that ALT-PTK6 reduces PTK6 interactions by greater than 50% even at low ratios. D) GST pull-down experiments were performed with GST alone or
GST-ALT-PTK6. Association of known PTK6 substrates b-catenin [23] and SAM68 [50] with ALT-PTK6 was detected by immunoblotting.
doi:10.1371/journal.pone.0014789.g002
ALT-PTK6 Regulates PTK6
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proline-rich SH2-catalytic domain linker region [47]. We were not
able to detect stable association of ALT-PTK6 with full-length
PTK6 protein (Figure 2B).
PTK6 is phosphorylated at several tyrosine residues including
tyrosine 342, which enhances its catalytic activity [4,47].
Phosphorylation of the carboxy-terminal tyrosine 447 negatively
regulates PTK6 activity [47,50], but since this residue is mutated
to phenylalanine in the PTK6 YF mutant, decreased PTK6
tyrosine phosphorylation likely represents decreased activating
phosphorylation. ALT-PTK6 also decreased association of PTK6
with tyrosine-phosphorylated proteins (Figure 2B and C). ALT-
PTK6 might compete for substrate interactions mediated by the
PTK6 SH3 domain, thus preventing PTK6 kinase from binding
with interacting proteins and phosphorylating its substrates. ALT-
PTK6 may also prevent other kinases from phosphorylating PTK6
if these associate through the PTK6 SH3 domain. We found that
ALT-PTK6 associates with endogenous Sam68 and b-catenin in
PC3 cells (Figure 2D), supporting the idea that ALT-PTK6 may
affect signaling outcomes involving these proteins.
Activation of the Wnt pathway and b-catenin/TCF transcrip-
tion contributes to cancer growth. Previously, we showed that b-
catenin transcriptional activity is repressed by nuclear-targeted
PTK6 [23]. Recently we showed that cytoplasmic PTK6 promotes
growth of prostate cancer cells. Knockdown of endogenous PTK6
protein that is largely localized to the cytoplasm resulted in
decreased PC3 cell proliferation. In contrast, reintroduction of
PTK6 protein into the nucleus led to growth inhibition [25]. Here
Figure 3. ALT-PTK6 enhances PTK6-mediated inhibition of b-catenin/TCF transcriptional activity by promoting the nuclear function
of PTK6. A) HEK293 cells were transfected with the Super 8x TOPFlash (TOPFlash) luciferase reporter construct, the control luciferase reporter
(FOPFlash), b-catenin, vector (-), or ALT-PTK6. b-catenin/TCF transcriptional activity in HEK293 cells was not affected when ALT-PTK6 was expressed in
the absence of PTK6. B) Transfections were performed as in (A), with the addition of PTK6 YF as indicated. ALT-PTK6 promotes the PTK6 YF mediated
inhibition of b-catenin transcriptional activity. Asterisks correspond to P-values of ,0.005 (**), and ,0.01 (*). C) Immunoblot analysis of fractionated
HEK293 cells expressing PTK6 YF and ALT-PTK6. ALT-PTK6 enhances nuclear localization of PTK6. b-catenin transcriptional activity is inhibited by PTK6
in the nucleus, but membrane-associated PTK6 results in increased b-catenin transcriptional activity [23]. E-cadherin and Sp1 were used as loading
controls. D) Quantification of membrane and nuclear pools of PTK6 YF. Increasing levels of ALT-PTK6 results in reduced PTK6 in the membrane
fraction (black bars) and increased nuclear PTK6 (white bars). Membrane PTK6 was normalized to E-cadherin, and nuclear PTK6 was normalized to
Sp1.
doi:10.1371/journal.pone.0014789.g003
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translocation of the full length PTK6 protein (Figure 3C) and
enhances the ability of PTK6 to repress transcription of a b-
catenin/TCF reporter construct (Figure 3B). Accordingly, intro-
duction of increasing levels of ALT-PTK6 led to decreased
expression of endogenous b-catenin/TCF targets in PC3 cells
(Figure 4). In addition, induction of ALT-PTK6 in PC3 cells led to
reduced growth and colony formation (Figure 5). This is
significant, because these data indicate that ALT-PTK6 has the
potential to inhibit Wnt/b-catenin/TCF signaling and aberrant
growth in prostate cancer.
A possible model of how ALT-PTK6 might influence signaling
is proposed in Figure 6. In cancer cells, PTK6 promotes oncogenic
signaling at the membrane and in the cytoplasm through
interactions with growth factor receptors and cytoplasmic
substrates such as IRS4, paxillin, STATs, (reviewed in [1,22]),
and AKT [40]. Recently we found that PTK6 is able to directly
phosphorylate and promote activation of cytoplasmic AKT [40].
When ALT-PTK6 is present (or if the balance shifts in the favor of
ALT-PTK6) it can compete for SH3-mediated interactions of
PTK6 substrates and binding partners. This competition may
result in a reduction of membrane associated PTK6, and allow
free pools of PTK6 to enter the nucleus, where it could mediate
growth inhibitory functions by regulating b-catenin, Sam68, or
PSF. ALT-PTK6 might also block associations of other proteins
beside PTK6 through its SH3 domain, and perhaps also through
the unique proline-rich carboxyl-terminus which is conceptually
capable of interacting with unknown SH3 domains. The total
effect of ALT-PTK6 expression in cancer cells may be negative
growth regulation (Figure 5B and C). The SRC-related FYN
tyrosine kinase was recently reported to have alternatively spliced
isoforms that affect the SH2-kinase domain linker region that is
recognized by the FYN SH3 domain, resulting in altered
autoinhibition as well as altered SH3-mediated substrate recogni-
tion [59].
Our findings suggest that it is important to consider ALT-PTK6
when targeting PTK6 therapeutically. The ability of ALT-PTK6
to influence the intracellular localization of the full length protein
Figure 4. ALT-PTK6 decreases expression of b-catenin/TCF
transcriptional targets in prostate tumor cells. A) Co-transfection
of PTK6 YF and ALT-PTK6 expression constructs into PC3 cells results in
reduced expression of the b-catenin/TCF transcriptional targets Cyclin
D1 and c-Myc. Levels of endogenous b-catenin were not affected, and
b-actin was used as a loading control. The pcDNA3 vector was used to
keep the total amount of transfected DNA equal. B) Quantification of
Cyclin D1 (white bars), c-Myc (grey bars), and b-catenin (black bars)
normalized to b-actin.
doi:10.1371/journal.pone.0014789.g004
Figure 5. ALT-PTK6 inhibits the growth of PC3 prostate tumor
cells. A) The intracellular localization of tetracycline-induced ALT-PTK6
was examined by immunofluorescent staining (left) and fractionation
(right) using Myc-epitope specific antibody. Immunofluorescent stain-
ing shows ALT-PTK6 (green) is cytoplasmic in PC3 cells that were
tetracycline-induced for ALT-PTK6 expression. The IgG control used
normal serum in place of Myc-epitope specific antibody to show
background staining in tetracycline-induced cells. Nuclei are visualized
with DAPI (blue). The size bar corresponds to 20 mm. Fractionation of
PC3 cells following tetracycline induction of ALT-PTK6 (ALT) shows that
ALT-PTK6 localizes to the cytoplasmic compartment. Tetracycline-
treated PC3 cells containing vector were used as a control (Vec).
Tubulin, ErbB2, and Sp1 serve as markers for the cytoplasmic,
membrane, and nuclear fractions respectively. B) A significant decrease
in PC3 cell growth is detected when ALT-PTK6 is induced (dotted line, +
Tet) compared with uninduced (solid line, - Tet) conditions. C) Colony
formation assay of stable ALT-PTK6 inducible PC3 cells which generate
colonies when untreated (-Tet). Colony formation is inhibited when
ALT-PTK6 expression was induced (+Tet). Asterisks correspond to P-
values of ,0.01 (*) and ,0.007 (**).
doi:10.1371/journal.pone.0014789.g005
ALT-PTK6 Regulates PTK6
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influence cell signaling pathways and growth. Fully understanding
the functions of ALT-PTK6 could aid in developing a small
peptide that could specifically promote PTK6 nuclear functions,
and restore regulation of nuclear PTK6 substrates such as Sam68
and PSF, as well as inhibiting b-catenin/TCF transcriptional
activity in prostate cancer cells.
Materials and Methods
Ethics statement
The tissues from which primary cell cultures were derived were
obtained with written informed consent under approval by the
Institutional Review Board at Stanford University (protocol ID
13895) and in compliance with the Helsinki Declaration.
Cell lines and tissue culture
Most cell lines including the human prostate adenocarcinoma
cell lines PC3 and DU145, the human colon adenocarcinoma cell
lines HCT116 and SW480, the embryonic kidney cell line
HEK293, and the human hepatoma cell line HepG2 were
obtained from ATCC (Manassas VA), and cultured as recom-
mended by ATCC. The benign prostatic hyperplasia epithelial cell
line BPH-1 (a gift from Dr. Simon Hayward (Vanderbilt
University, Nashville TN)) was cultured in RPMI-1640 containing
5% fetal bovine serum, 100 U/ml penicillin and 100 mg/ml
streptomycin [60]. Primary cultures from the peripheral zone of
normal human prostate and from primary prostate adenocarci-
nomas were established and characterized according to previously
described methods [61,62]. Tetracycline-inducible PC3 cells were
cultured with tetracycline-free fetal bovine serum (Gemini Bio-
Products, West Sacramento CA).
For colony formation assays stable tetracycline inducible cells
were serum starved for 48 hours and induced with 1 mg/ml
tetracycline (Sigma, St. Louis MO) if applicable. Cells were then
trypsinized, counted and 1.7610
4 cells seeded per well in a 6-well
tissue culture plate and cultured as parental PC3 cells with
tetracycline if appropriate. After 10 days the cells were fixed with
ice cold methanol for 10 minutes and colonies were stained using
0.5% crystal violet.
Plasmid constructs and stable cell lines
For ectopic expression of PTK6, the constitutively active
pcDNA3-Myc-PTK6 YF (PTK6 YF) construct was used, which
has the negatively regulatory tyrosine 447 mutated to phenylal-
anine. The pcDNA3 vector was used as a control and to keep total
amount of plasmid DNA constant for co-expression experiments.
Tetracycline inducible plasmid constructs were made using the
pcDNA4/TO vector (Invitrogen, Carlsbad CA) linearized using
HindIII endonuclease (Invitrogen). The 2.1 kb products of the
HindIII digests of pcDNA3-Myc-ALT-PTK6 were gel extracted
and ligated with the pcDNA4/TO vector backbone. Constructs
were sequenced using CMV-forward (59-CGCAAATGGG
CGGTAGGCGT G-39) and BGH-reverse (59-TAGAAGGCAC
AGTCGAGG-39) primers. For generation of the GST-ALT-
PTK6 expression construct, pGEX-2TK vector (GE Healthcare,
Piscataway NJ) was linearized using Sma I and the gel extracted
ALT-PTK6 fragment, which was excised from the expression
construct using Xma I and Hind III followed by filling in
overhangs, was ligated to the vector backbone in-frame with GST.
GST-ALT-PTK6 protein was produced by transforming BL21
bacteria that were allowed to grow at 37uC to an optical density of
0.8-1.0 before induction with IPTG for 2 hours and purification
using Glutathione sepharose 4B beads (GE Healthcare).
The PC3 human prostate tumor cell line was transfected with
pcDNA6/TR (Invitrogen) using lipofectamine as per manufactur-
er’s instructions. Cells were plated sparsely and transfected cells
were selected with 2 mg/ml blasticidin (Invitrogen) over a two-
week period. Single colonies of the PC3-TR (Tet Repressor) cells
were isolated, expanded, and screened by transient transfection
Figure 6. ALT-PTK6 may regulate activities of full-length PTK6. PTK6 may promote oncogenic signaling by phosphorylation and association
with transmembrane and cytosolic proteins. ALT-PTK6 can compete for SH3 interaction with PTK6 and probably other proteins through its SH3
domain (and potentially the proline-rich carboxy terminal tail). In the case of PTK6 this results in reduced PTK6 tyrosine phosphorylation, reduced
interaction with other tyrosine-phosphorylated proteins, reduced membrane association, and increased nuclear function; at least some of these
factors contribute to growth regulation such as negative regulation of b-catenin/TCF signaling.
doi:10.1371/journal.pone.0014789.g006
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of 1 mg/ml tetracycline (data not shown). A clone with no
detectable expression in the absence of tetracycline was used for
subsequent stable cell lines.
For stable tetracycline-inducible cells, PC3-TR cells were
transfected with pcDNA4/TO-Myc-ALT-PTK6 and selected as
above, adding 200 mg/ml of Zeocin (Invitrogen). Several clones
were expanded for each cell line and screened with and without
tetracycline addition by both immunoblotting and immunofluo-
rescence staining to determine expression.
Sequencing and PCR analysis of PTK6 RNA
RNA was isolated with TRIzol (Invitrogen) as per manufactur-
er’s instructions. For generating cDNA, 5 mg of total RNA was
reverse transcribed using random hexamer primers as per
manufacturer’s suggestion (Invitrogen). Two mL of the reaction
was used to amplify PTK6 cDNA for 35 cycles at 72uC using the
primers 59-CCTGGGCCCC AAGTATGT-39 (forward) and 59-
CAGAATTCCA TGGATGAAAG AGACACC-39 (reverse). The
products from the PCR were cloned into pBluescriptKSII(-), four
colonies of transformed DH5a were picked, plasmids isolated, and
sequenced. Sequences were aligned with PTK6 mRNA (Accession
NM_005975).
Semi-quantitative PCR of cDNA samples of PTK6 transcripts
was done using two sets of human PTK6 primers. Set 1: the
forward primer 59-GCTATGTGCC CCACAACTAC C-39
specific to exon 1, and the reverse primer 59-CCTGCAGAGC
GTGAACTCC-39 specific to exon 3; Set 2: the forward primer 59-
TGTGCCCCAC AACTACCTGG-39 specific to exon 1, and the
reverse primer 59-TGCAGAGCGT GAACTCCTCC-39 specific
to exon 3. The PCR reaction was carried out using an annealing
temperature of 63uC for 30 cycles. Human b-actin forward
primer: 59-AAAATCTGGC ACCACACCTT CTAC-39, and
reverse primer: 59- TAGCACAGCC TGGATAGCAA CG -39
were used to measure b-actin levels in cDNA samples as a control.
PCR reactions were separated on 1.5% agarose gels and stained
with ethidium bromide. Quantitation was performed using the
public domain NIH ImageJ program [63].
Quantitative Real Time PCR amplification was done in
triplicate using primers specific for PTK6 exon 2 (PTK6-
X2_For 59-CGGAACCGTG GTTCTTTG-39 and PTK6-
X2_Rev 59-ACTCGGCTTC TCGCTGAC-39) and exon 8
(PTK6-X8_For 59-TGTTCCTGCT CTTCCCAGTT-39 and
PTK6-X8_Rev 59-TGGGAGGAAA GAACCCTTGA-39)a s
described previously [64]. The levels of PTK6 transcripts were
normalized against the levels of cyclophilin mRNA which was
used as an internal control, and for comparison of different exons,
starting quantities were also normalized to a PTK6 plasmid
control to adjust for variations in primer efficiencies between
different exons.
Immunofluorescent staining
Ten thousand PC3 cells were added per well on a 4-chamber
culture slide (BD Biosciences, Bedford MA) and cells were allowed
to attach for 24–48 hours. Cells were fixed with Carnoy’s fixative
(60% ethanol, 30% chloroform, 10% glacial acetic acid). Primary
Myc-epitope antibody (Cell Signaling Technologies Inc., Boston
MA) was diluted 1:250 in 3% BSA (bovine serum albumin) in
TNT buffer (100 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.05%
Tween 20), incubated at 4uC overnight, and then detected with
fluorescein isothiocyanate (FITC)-conjugated anti-mouse IgG
(Sigma). Cells were incubated for 5 minutes in 2 mg/ml 49,6-
diamidino-2-phenylindole (DAPI) (Sigma), rinsed twice with TNT
buffer, and mounted with mounting media (Vector Laboratories
Inc., Burlington CA).
Fractionation, immunoblotting, GST pull-down assays
and immunoprecipitation
Total cell lysates were harvested and immunoblotting was done
as described previously [14]. PC3 total cell lysates were used for
GST-pull down assays with GST and GST-ALT-PTK6 fusion
proteins [14]. Fractionation of stable inducible ALT-PTK6 PC3
cells was carried out using the ProteoExtract Subcellular
Proteosome Extraction Kit (Calbiochem, San Diego CA) as per
manufacturer’s instructions. Ten percent of the final volume for
each fraction was used. Antibodies against Cyclin D1, E-cadherin,
Neu/ErbB2, c-Myc, and Sp1 were obtained from Santa Cruz
Biotechnology (Santa Cruz CA); anti-Myc-tag antibody was
purchased from Cell Signaling Technologies; antibodies specific
to b-actin and a-tubulin were obtained from Sigma; b-catenin
specific antibody was purchased from BD Transduction Labora-
tories. For detection of phosphotyrosine proteins, a combination of
anti-phosphotyrosine antibodies from Upstate/Millipore (4G10)
and Santa Cruz (PY20) was used. For immunoprecipitation,
500 mg of total cell lysates were used as described previously [23],
using 1 mg of mouse anti-Myc-tag (Cell Signaling Technologies
Inc.) for pull-down. Quantitation of blots was performed using the
public domain NIH ImageJ program [63].
Luciferase reporter assay
Luciferase assays were conducted as described previously [23].
In brief, to determine the effects of ALT-PTK6 on b-catenin/TCF
transcription, and transcriptional inhibition by PTK6, HEK293
cells were co-transfected with Super 8X TOPflash [51] (a gift from
Dr. Randall Moon, University of Washington) containing eight
TCF/Lef binding sites (TOPflash), b-catenin, PTK6 YF and
ALT-PTK6. Renilla was used as a control for transfection
efficiency to normalize values; vector was used to keep total
amount of plasmid DNA constant. The transcriptionally dead
Super 8X FOPflash (FOPflash) was used as a negative control.
Luciferase activity was assessed 24 hours after transfection using
the Dual-Luciferase Reporter Assay System (Promega, Madison
WI) and the Clarity Microplate Luminometer (BioTek Instru-
ments Inc., Winooski VT). At least three independent experiments
were performed in duplicate.
Supporting Information
Figure S1 Quantitative PCR of PTK6 transcripts containing
exon 2 and exon 8. A) Quantitative real-time PCR analysis of
PTK6 transcripts using primers specific to exon 2 (X2) of the full-
length PTK6 transcript and exon 8 (X8) of ALT-PTK6 and PTK6
transcripts. B) Values for both exons were normalized to
cyclophilin loading control and PTK6 expression construct (which
contains exon 2 and exon 8 sequences in a 1:1 ratio). C) The ratios
of normalized PTK6 exon 8 to exon 2 were determined for each
cell line, and do not show a particular trend with regards to the
primary tumor site from which the cell lines were derived.
Found at: doi:10.1371/journal.pone.0014789.s001 (0.10 MB TIF)
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